Endo Health Solutions has talked in recent weeks with other pharmaceutical companies about buying the Chadds Ford-based drugmaker, Reuters reported Wednesday.
A link to the Reuters story is here.
The talks involved Warner Chilcott Plc and Valeant Pharmaceuticals International Inc., Reuters reported, citing sources it did not identify.
In an email to the Inquirer, Endo spokesman Kevin Wiggins said, "As a matter of company policy, we do not comment on market speculation."
Endo's top products are painkillers and it faces regulatory issues and generic competition. The company's Lidoderm patch and Opana ER tablets are among its best-selling products, but both will soon have generic competition. With the rise in deaths due to overdoses of prescription painkillers, government agencies have looked more closely at how drug companies and their wholesalers make and distribute those medicines.
In December, Endo chief executive officer Dave Holveck announced he would retire this year. The company has been planning to move into a new headquarters in Malvern.
Warner Chilcott is headquartered in Ireland but its main U.S. office is in Rockaway, N.J.
Valeant is headquartered in Montreal, with its U.S. headquarters in Bridgewater, N.J. In 2011, Valeant mounted a public - and eventually unsuccessful - challenge to Teva Pharmaceuticals' purchase of Frazer-based Cephalon.